article thumbnail

Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk

Pharmaceutical Technology

Using data from the UK Biobank database, genomic sequencing data for 360,000 individuals were obtained and the findings were confirmed in animal models that demonstrated a higher expression of the INHBE gene in obese monkeys when compared to more lean monkeys.

Gene 130
article thumbnail

UMC Utrecht receives grant for microbiota-boosted cancer therapy 

Drug Discovery World

As part of the study, a large biobank of patient material from cancer patients prior to and during ICI therapy will be investigated, immune-stimulatory bacteria will be identified and isolated, and molecular mechanisms will be unraveled using various in vitro and in vivo models. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reflecting on ELRIG’s Drug Discovery 2022 

Drug Discovery World

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52
article thumbnail

CENTOGENE Opens Walk-In COVID-19 Testing Facility at Berlin Brandenburg Airport

The Pharma Data

CENTOGENE’s SARS-CoV-2 test is a molecular diagnostic test performed for the in vitro qualitative detection of RNA from the SARS-CoV-2 in oropharyngeal samples from presymptomatic patients and probands according to the recommended testing by public health authority guidelines. CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.